LymphMark™ Assay is a 20-gene signature novel, genomic lymphoma subtyping in vitro diagnostic test, used on the nCounter Flex Analysis System. It is based on the Lymph2Cx gene signature that was originally developed by the Lymphoma/Leukemia Molecular Profiling Project (LLMPP). The LymphMark test utilizes gene-expression profiling of RNA extracted from formalin-fixed paraffin-embedded tissue to classify the “cell of origin” subtype of DLBCL tumors.